Skip to main navigation

Home
Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Financials
Governance
IR Resources
- Email Alerts
- Contact IR

Press Releases

Press Releases

Year

October 1, 2020

Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's Disease

September 22, 2020

Athira Pharma Announces Closing of Initial Public Offering

September 17, 2020

Athira Pharma Announces Pricing of Initial Public Offering

June 4, 2020

Athira Pharma Closes $85 Million Series B Financing

May 28, 2020

Athira Pharma to Present at Jefferies Virtual Global Healthcare Conference

December 9, 2019

Athira Pharma Presents Positive Data for NDX-1017 in Alzheimer's Patients at 2019 Clinical Trials on Alzheimer's Disease (CTAD) Conference

November 20, 2019

Athira Pharma to Present Phase 1 Data for NDX-1017 in Oral Presentation at 2019 Clinical Trials on Alzheimer's Disease (CTAD) Conference

October 2, 2019

Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimer's Patients

July 16, 2019

Athira Pharma Presents Preliminary Results from Phase 1 Trial of NDX-1017 at Alzheimer's Association International Conference 2019 (AAIC)

July 11, 2019

Athira Pharma Announces Appointment of Mark Litton as Chief Operating Officer

Pagination

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Next page
Last page

Displaying 81 - 90 of 93

SIGN UP FOR EMAIL ALERTS

CONTACT IR

Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

Main line: (866) 725-0930
Local number: (425) 620-8501
info@athira.com

© Athira Pharma, Inc. All rights reserved.